Summary
Amgen Inc. (AMGN) has filed an 8-K report detailing a significant debt offering and the subsequent redemption of existing debt. On May 20, 2008, the company entered into an underwriting agreement to issue and sell $1 billion in aggregate principal amount of senior notes, split equally between 6.15% Senior Notes due 2018 and 6.90% Senior Notes due 2038. This offering, which closed on May 23, 2008, generated net proceeds of approximately $990.9 million after accounting for underwriter discounts and expenses. The primary purpose of this debt issuance was to fund the redemption of $1.0 billion of Amgen's outstanding Senior Floating Rate Notes due 2008. This move indicates a strategic financial management decision to refinance maturing debt with longer-term, fixed-rate obligations, potentially to lock in borrowing costs and manage interest rate risk.
Key Highlights
- 1Amgen Inc. issued $1 billion in new senior notes: $500 million of 6.15% Senior Notes due 2018 and $500 million of 6.90% Senior Notes due 2038.
- 2The notes were issued under an effective registration statement on Form S-3 and pursuant to an indenture dated August 4, 2003.
- 3Net proceeds from the offering amounted to approximately $990.9 million.
- 4The proceeds are earmarked for the redemption of $1.0 billion of Amgen's Senior Floating Rate Notes due 2008.
- 5The new notes rank equally with Amgen's other existing and future senior unsecured indebtedness.
- 6A change in control triggering event may allow noteholders to require Amgen to purchase their notes at 101% of the principal amount plus accrued interest.
- 7The filing includes the Underwriting Agreement, the Indenture, and an Officers' Certificate as exhibits.